23.81
+0.15
+(0.63%)
At close: January 24 at 3:00:03 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
41,611,309.54
41,399,539.59
43,951,546.90
39,011,184.28
30,306,981.26
Cost of Revenue
21,705,387.14
21,595,308.76
23,169,690.42
20,229,784.68
13,733,528.78
Gross Profit
19,905,922.40
19,804,230.83
20,781,856.48
18,781,399.60
16,573,452.48
Operating Expense
17,155,771.78
18,240,906.77
17,145,016.83
16,071,626.61
13,743,289.52
Operating Income
2,750,150.62
1,563,324.06
3,636,839.65
2,709,772.99
2,830,162.97
Net Non Operating Interest Income Expense
-1,095,835.93
-997,350.08
-709,762.38
-618,688.82
-699,483.24
Pretax Income
3,043,677.27
3,264,567.88
4,574,381.58
6,042,670.59
4,677,844.35
Tax Provision
283,905.75
369,504.45
626,917.46
1,066,401.22
737,864.58
Net Income Common Stockholders
2,113,842.24
2,386,265.81
3,730,804.58
4,728,710.53
3,662,812.94
Basic EPS
0.78
0.89
1.43
1.85
1.43
Diluted EPS
0.78
0.89
1.43
1.85
1.43
Basic Average Shares
2,700,794.03
2,681,197.54
2,608,954.25
2,556,059.75
2,561,407.65
Diluted Average Shares
2,700,794.03
2,681,197.54
2,608,954.25
2,556,059.75
2,561,407.65
Total Operating Income as Reported
3,072,898.95
3,307,507.91
4,656,656.38
6,302,568.21
4,721,145.27
Total Expenses
38,861,158.92
39,836,215.53
40,314,707.25
36,301,411.29
27,476,818.30
Net Income from Continuing & Discontinued Operation
2,113,842.24
2,386,265.81
3,730,804.58
4,728,710.53
3,662,812.94
Normalized Income
3,394,842.53
3,072,203.21
6,069,937.75
5,195,654.90
3,383,792.37
Interest Income
377,741.78
363,645.39
282,634.64
233,727.10
199,608.71
Interest Expense
1,445,036.90
1,324,830.53
963,806.92
822,534.03
880,952.45
Net Interest Income
-1,095,835.93
-997,350.08
-709,762.38
-618,688.82
-699,483.24
EBIT
4,488,714.17
4,589,398.40
5,538,188.50
6,865,204.62
5,558,796.80
EBITDA
4,488,714.17
7,554,583.03
7,874,099.75
8,699,592.89
7,225,018.17
Reconciled Cost of Revenue
21,705,387.14
21,595,308.76
23,169,690.42
20,229,784.68
13,733,528.78
Reconciled Depreciation
--
2,965,184.63
2,335,911.25
1,834,388.27
1,666,221.37
Net Income from Continuing Operation Net Minority Interest
2,113,842.24
2,386,265.81
3,730,804.58
4,728,710.53
3,662,812.94
Total Unusual Items Excluding Goodwill
-1,412,780.52
-773,485.37
-2,710,623.17
-567,009.30
331,274.49
Total Unusual Items
-1,412,780.52
-773,485.37
-2,710,623.17
-567,009.30
331,274.49
Normalized EBITDA
5,901,494.69
8,328,068.40
10,584,722.91
9,266,602.19
6,893,743.68
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-131,780.24
-87,547.97
-371,490.00
-100,064.93
52,253.92
12/31/2020 - 8/7/1998
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
4540.T Tsumura & Co.
4,528.00
+0.33%
4887.T Sawai Group Holdings Co., Ltd.
2,027.00
+0.67%
4521.T Kaken Pharmaceutical Co., Ltd.
4,292.00
+1.35%
600085.SS TONGRENTANG
36.75
+0.14%
600079.SS HUMANWELL HEALTHCARE
21.89
-0.27%
4530.T Hisamitsu Pharmaceutical Co., Inc.
4,642.00
+0.04%
002001.SZ Zhejiang NHU Company Ltd.
22.49
+0.40%
000999.SZ China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
44.18
+0.61%
000963.SZ Huadong Medicine Co., Ltd
34.11
-0.93%
ALKEM.BO Alkem Laboratories Limited
5,026.80
-2.95%